NASDAQ:FULC Fulcrum Therapeutics Q2 2025 Earnings Results & Report $3.74 +0.02 (+0.40%) As of 11:16 AM Eastern This is a fair market value price provided by Massive. Learn more. Fulcrum Therapeutics beat analyst earnings expectations in its Q2 2025 results, released July 29, 2025. The company reported EPS of -$0.28 versus the -$0.29 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateJuly 29, 2025TimeBefore Market OpensConference Call4:00 PM ET Fulcrum Therapeutics EPS ResultsActual EPS-$0.28Consensus EPS -$0.29Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersFulcrum Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Fulcrum Therapeutics Q2 2025 Earnings FAQ Did Fulcrum Therapeutics beat earnings estimates for Q2 2025? Fulcrum Therapeutics (NASDAQ:FULC) reported earnings of -$0.28 per share for Q2 2025, beating the consensus estimate of -$0.29. The report was announced on Tuesday, July 29, 2025. Fulcrum Therapeutics Earnings HeadlinesFulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULCNovember 17 at 5:20 PM | businesswire.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded at Wall Street ZenNovember 17 at 3:19 AM | americanbankingnews.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 19 at 1:00 AM | Base Camp Trading (Ad)Fulcrum Therapeutics (NASDAQ:FULC) Stock Crosses Above 50-Day Moving Average Following Weak EarningsNovember 15, 2026 | americanbankingnews.comFulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13, 2026 | marketscreener.comMFulcrum Therapeutics consensus price target decreased by 10.09% to $6.97November 3, 2026 | msn.comSee More Fulcrum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulcrum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your email. Email Address About Fulcrum TherapeuticsFulcrum Therapeutics (NASDAQ:FULC) is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity. Founded in 2016, Fulcrum conducts drug discovery and development primarily in the United States. Its programs and development priorities may change as clinical research progresses.View Fulcrum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletTarget Stock Is Up Over 70%—Has the Easy Money Already Been Made?TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off Upcoming Earnings Agilent Technologies (11/23/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.